Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Brokerages

Key Points

• Astria Therapeutics has a consensus recommendation of "Buy" from seven brokerages, with six analysts providing a buy and one a strong buy recommendation, and an average price target of $29.00.
• Institutional investors control 98.98% of Astria's stock, with notable increases in positions from institutions like JPMorgan Chase & Co. and Wells Fargo during the fourth quarter.
• The company reported a quarterly EPS of ($0.57), exceeding the consensus estimate, while analysts expect an average EPS of -1.65 for the current fiscal year.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $29.00.

Several research firms have commented on ATXS. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, August 13th. JMP Securities raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a report on Wednesday, August 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th.

Astria Therapeutics Stock Up 0.3%

Shares of ATXS traded up $0.02 during mid-day trading on Tuesday, hitting $6.53. 236,545 shares of the company traded hands, compared to its average volume of 266,293. Astria Therapeutics has a 1-year low of $3.56 and a 1-year high of $12.92. The business has a 50 day moving average of $6.37 and a 200 day moving average of $5.71. The company has a market capitalization of $368.55 million, a PE ratio of -3.25 and a beta of 0.48.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. As a group, research analysts expect that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP increased its stake in shares of Astria Therapeutics by 8.2% in the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock worth $24,238,000 after acquiring an additional 342,000 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Astria Therapeutics by 117.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 103,566 shares of the biotechnology company's stock worth $555,000 after acquiring an additional 56,006 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Astria Therapeutics by 24.9% in the 2nd quarter. Bank of America Corp DE now owns 49,628 shares of the biotechnology company's stock worth $266,000 after acquiring an additional 9,881 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Astria Therapeutics by 48.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company's stock worth $4,690,000 after acquiring an additional 286,800 shares during the last quarter. Finally, PDT Partners LLC increased its position in shares of Astria Therapeutics by 90.3% during the 2nd quarter. PDT Partners LLC now owns 54,642 shares of the biotechnology company's stock worth $293,000 after purchasing an additional 25,935 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.